Baxter International Inc. (BAX) recently received marketing authorization for CELVAPAN H1N1 vaccine, commonly known as the Swine Flu vaccine, in the European Union. The company has already delivered limited quantities of H1N1 vaccine to a few countries, such as the UK and Ireland, as part of their national vaccination programs.

Presently, Baxter is conducting two clinical trials to confirm the safety and immunogenicity of CELVAPAN H1N1. These trials encompass 400 healthy adults who are 18 years and above, besides 400 children and adolescents. The safety and immunogenicity of CELVAPAN H1N1 in these trials are conducted at dose levels of 7.5µg and 3.75µg, respectively. Baxter also plans to conduct a large-scale study of CELVAPAN in 9,000 people of different age groups including children.

Preliminary safety data in adults for 7.5µg doses of vaccine indicated that the vaccine was well tolerated in these age groups. The reactions were also similar to seasonal influenza vaccines. Two 7.5µg doses of vaccine were administered in a span of 21 days. Immunogenicity data from this study are due within days. This will indicate whether a single dose of vaccine is sufficient to induce the necessary immune response.

Another study for 3.75µg doses of vaccine will indicate whether a lower dose is sufficient to induce the necessary immune response or not.??Baxter is a leading global medical products and services company that develops, manufactures and markets products to save the lives of millions of people affected by hemophilia, kidney diseases, infectious diseases, etc.

Baxter’s life-sustaining product portfolio is a hedge against the current economic turmoil. The company’s main competitors include Becton, Dickinson and Co. (BDX) and Johnson & Johnson (JNJ).

Zacks Investment Research
View original at: Zacks.com News Feed

1. (BAX) Baxter International’s H1N1 Vaccine Gets a BoostBaxter International Inc. (BAX) announced that the European Medicines Agency (EMEA) opined positively for Baxter’s...
2. (BAX) Baxter International – Bullish Earnings ProjectionsBaxter International (BAX) is seeing bullish earnings projections. The current full-year Zacks Consensus Estimate of...
3. (BAX) Baxter International Discussed Long-Term GoalsBaxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and...
4. (BAX) Baxter International Fails to Deliver Swine Flu VaccineBaxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government...
5. (SNY) FDA Approves First H1N1 VaccineIn a major achievement towards vaccinating people against the H1N1 virus, yesterday the US Food...
6. ($BAX) Baxter International – ROE of 35%, soaring past the industry average of 8%$Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the...

Search Posts by Tag: BAX | Baxter International Inc | BDX | Becton | Dickinson And Company | JNJ | Johnson & Johnson | Healthcare

RSS Feeds by Tag: BAX | Baxter International Inc | BDX | Becton | Dickinson And Company | JNJ | Johnson & Johnson | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author